Previous studies have reported differences in the use of cardiovascular medications for acute coronary syndromes (ACSs) according to the sex of the patient. We analysed which clinical factors are associated with underutilization of evidence-based therapies in women.
Introduction
Previous studies have reported differences in the use of cardiovascular procedures and medications for acute coronary syndromes (ACSs) according to the sex of the patient. 1 -10 Although this evidence suggests that physician bias is a contributor to such disparities, the nature of this bias is unclear. 11 Potential sources of bias may include differences in treating physician's perception of risk, lower priority assigned to evidencebased therapies compared with concomitant use of other medications, and older age. 12 To contribute to a better understanding of the clinical decisionmaking process in women, we analysed which factors are associated with underutilization of evidence-based therapies in ACSs.
Methods Participants
The Canadian ACS Registries were prospective, multi-centre, observational studies designed to examine in-hospital and post-discharge management, and outcomes of patients with ACSs. Detailed descriptions of patients and methods have been published previously. 13, 14 In brief, † A list of participating Canadian ACS Registries I and II Investigators and Co-ordinators may be found in the Arch Intern Med 2007;167: 1009 -1016. the study population consisted of patients older than 18 years admitted to the hospital with symptoms consistent with acute cardiac ischaemia with onset ,24 h and not precipitated by significant co-morbidities such as trauma or gastrointestinal bleeding. To minimize the selection bias, there were no other specific exclusion criteria. Between September 1999 and June 2001, 5312 patients from 51 hospitals in nine provinces were recruited into the Canadian ACS Registry I. The ACS Registry II enrolled 2359 patients from 36 hospitals in seven provinces with suspected non-ST-elevation ACS from October 2002 to December 2003. Of the 51 and 36 participating hospitals in ACS Registries I and II, 29 and 33% had on-site cardiac catheterization laboratories, and 41 and 42% had teaching affiliations, respectively. Of these patients, 6558 (85.4% of all patients enrolled) had a final ACS diagnosis according to the treating physician. The local research Ethics Committee approved the study protocol. All patients participating in the 1-year follow-up after hospital discharge provided written informed consent.
Study variables and data collection
Patient demographics, cardiovascular risk factors, presenting clinical and electrocardiographic features, relevant laboratory investigations, medication use at discharge, use of diagnostic and therapeutic interventional procedures, and adverse in-hospital outcome were collected by the designated physician or study co-ordinator on standardized case report forms. Serial electrocardiograms and measurements of biomarkers of myocardial necrosis were used by the treating physician to determine the diagnosis (myocardial infarction with ST-segment elevation, myocardial infarction without ST-segment elevation, and unstable angina); myocardial infarction was identified in the presence of abnormal cardiac biomarkers as per local laboratory definitions within the first 24 h of admission. Cardiac procedures comprised all scheduled and unscheduled coronary angiography, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) surgery. All data were transmitted to the co-ordinating centre (Canadian Heart Research Centre, Toronto, Ontario, Canada) where quality-control efforts were made to ensure data completeness and accuracy in a central electronic database (Teleform, San Diego, CA, USA).
Post-discharge follow-up and outcomes
Post-discharge follow-up was conducted via central telephone interview of patients (if unavailable, via interview of their designated next-of-kin or primary care physician) at 1 year after enrolment. Information on medication use, use of any cardiac procedure, subsequent re-hospitalization for adverse cardiovascular events including recurrent non-fatal myocardial infarction, and all-cause mortality were recorded by trained interviewers on an electronic case report form.
Statistical analysis
We compared the baseline characteristics, discharge evidence-based therapies, and clinical outcome of men and women. Statistical testing was performed with the use of the x 2 test for categorical variables and the Wilcoxon rank-sum test for continuous variables. We performed multivariable logistic regression analysis to examine the relationships between patient characteristics and the use of evidencebased therapies [aspirin, angiotensin-converting enzyme (ACE)-inhibitors, beta-blockers, and lipid-modifying agents] and calculated the odd ratios (OR) and associated 95% confidence intervals (CI). To identify independent predictors, all candidate variables (listed in Tables 2 -4) were considered, and backward stepwise elimination (P , 0.05) was applied to arrive at the parsimonious model. Model calibration was evaluated by the Hosmer-Lemeshow goodness-of-fit test. For all analysis, statistical significance was defined as a value of P , 0.05. Data were analysed by the co-ordinating centre (Canadian Heart Research Centre, Toronto, Ontario, Canada). Statistical evaluation was performed using the SPSS 13.0 (SPSS Chicago, IL, USA).
Results
The study population consisted of 6558 patients, of whom 4471 were men and 2087 were women. The clinical characteristics of the study population are shown in Table 1 .
Women were older with a higher prevalence of hypertension and a history of congestive heart failure, but they were less likely to have a history of prior revascularization or to be smokers. Women less frequently presented with Killip class 1 and positive troponin; they had higher systolic blood pressure and heart rate, and lower serum creatinine level. They underwent fewer invasive procedures including angiography, PCI, and CABG surgery compared with men, and they had a significantly worse outcome compared with men.
Treatment disparities were present for discharge medication use except for anti-platelet agents. All statistically significant differences were 4% or more. Tables 2-4 show the results of the assessment of potential factors influencing underutilization of evidence-based therapies in our study population. All candidate predictors for drug utilization included in the analysis are listed in the Step 1 model. After testing them one by one for statistical significance, those that contributed least were eliminated at further steps. As the result of a successful discriminant function analysis, Step 10 indicates the model including those predictors that contribute the most to the discrimination between groups. The Hosmer-Lemeshow P-values were 0.54, 0.57, and 0.34 for beta-blockers, ACE-inhibitors, and lipid-modifying agents, respectively, indicating adequate fit. Compared with their counterparts in the ACS I Registry, ACS II Registry patients were more frequently (P , 0.001) treated with betablockers (OR: 1.85; 95% CI: 1.58 -2.17), ACE-inhibitors (OR: 1.65; 95% CI: 1.46-1.89), and lipid-modifying agents (OR: 3.96; 95% CI: 3.31-4.56). Table 2 shows the results for beta-blockers. Four variables remained significant negative predictors (P , 0.01) of their use after adjustment for potential confounding influences: age (OR: 0.95; 95% CI: 0.92-0.98), Killip class 2 (OR: 0.67; 95% CI: 0.60-0.81), Killip class 3/4 (OR: 0.61; 95% CI: 0.44-0.85), and heart rate (OR: 0.95; 95% CI: 0.92-0.98). Because non-significant variables were removed in stepwise regression, these four predictive variables showed stable and significant adjusted OR. We assessed the effect of potential confounding on ACE-inhibitor and lipid-lowering agent use by a second and third logistic regression analysis, respectively (Tables 3 and 4). Backward stepwise regression analysis indicated that increasing creatinine levels (OR: 0.67; 95% CI: 0.54 -0.88), no referral to cardiac catheterization (OR: 0.83; 95% CI: 0.66-0.98), CABG during hospitalization (OR: 0.68; 95% CI: 0.54-0.88), and female sex (OR: 0.74; 95% CI: 0.65-0.83) were significantly (P , 0.01) associated with decreased OR for ACE-inhibitor use. Increasing age (OR: 0.80; 95% CI: 0.75-0.84), female sex (OR: 0.77; 95% CI: 0.66-0.88), and no referral to cardiac catheterization (OR: 0.42; 95% CI: 0.14-0.65) were independent predictors (P , 0.01) for lipidmodifying agent under-prescription.
Multivariable analyses
With respect to the baseline characteristics already identified in the initial analysis as significantly more prevalent in the female population, there were three factors that were independent negative predictors of evidence-based therapy: age, Killip class ≥ 2, and lack to referral to cardiac catheterization. The only variable to favour the use of evidence-based therapy in the female population was a prior history of coronary bypass surgery.
Discussion
The findings demonstrate an underutilization of evidence-based treatments in women with ACSs. This disparity appears to depend largely upon multiple factors related to the patient (age), to consequences of the disease (congestive heart failure), and to the physician's assessment of patient risk (decision to catheterize).
Age
Several studies have found that as age increases, use of evidencebased treatment decreases, and have suggested that an age-sex Evidence-based therapies in women interaction may be responsible for the lower use of evidence-based care observed in women. 11, 12 Older patients are undertreated, though randomized clinical trial data have demonstrated mortality and morbidity benefits in these patients. 15 Concern about side effects may discourage clinicians from prescribing beta-blockers and lipid-lowering agents in the elderly, but in clinical practice absolute contraindications are rare. 16 The women in the Canadian ACS Registry population were nearly 5 years older than the men, on average, which, at first glance, could be taken to support this hypothesis. In our study, age was independently associated with lower use of beta-blockers (0.80 and OR: 0.83; 95% CI: 0.78-0.88) and lipid-lowering agents (OR: 0.80; 95% CI: 0.75-0.84) as recommended therapy at discharge. However, other variables remained independent predictors of beta-blocker (Killip class ≥ 2 and heart rate) and lipid-lowering agent (female sex and no referral to cardiac catheterization) underutilization. Age, therefore, does not appear to explain completely the observed treatment differences. Prior studies that failed to adjust for important baseline and treatment variables likely overestimated age as the only factor responsible for differences in ACS treatment between women and men.
Heart failure
In our adjusted analyses, clinical presentation influenced delivery of evidence-based care at discharge, as indexed by the independent association between heart failure (Killip class ≥ 2) and betablocker underutilization (OR: 0.67; 95% CI: 0.55 -0.80). Recent studies investigating prescribing patterns in heart failure have indicated that 70% of patients discharged receive beta-blockers at the 90-day post-discharge follow-up visit. 17 In the Euro Heart Survey, 49% of 11 304 patients with heart failure were prescribed beta-blocker at discharge. 18 Other studies have also reported similar findings. 19 In all of these studies, gender did not significantly influence beta-blockers use. Physicians are reluctant to initiate beta-blocker therapy in patients with acutely compromised systolic function either if patients are men or women. In the current analysis, underutilization of beta-blockers was more striking for the female population, as women more frequently developed heart failure during ACSs. 20 The reason for the greater incidence of heart failure in women is not clear but may in part be due to delayed treatment of women. Referral bias may also be implicated, with only the most severely affected women being diagnosed and treated. It is also conceivable that women may be predisposed to a highly aggressive disease, or a disease that in other ways differs in aetiology or manifestation from the more common disease of men.
Cardiac catheterization
Sex differences in coronary care have been described for at least 20 years, 3, 11 with women being referred to cardiac catheterization less often compared with men. Our findings are consistent with these results: 41.8% of women underwent cardiac catheterization, compared with 49.6% of men. The multivariable analysis identified the lack of catheterization as an independent predictor for underutilization of lipid-modifying agents (OR: 0.42; 95% CI: 0.14-0.65) and ACE-inhibitors (OR: 0.83; 95% CI: 0.66-0.98). It should be noted, however, that to be included in our study cohort, all patients had to have a diagnosis of ACS and, therefore, all should have received similar consideration and evidence-based therapies. The decision to catheterize was not an independent occurrence but presumably based on the perceived risk not necessarily captured by individual baseline characteristics. Although reduced rates of cardiac catheterization in women with troponin negative ACS are consistent with a relative lack of benefit in this subgroup, 21, 22 lack of catheterization should be to blame for the concurrent lack of evidence-based medical therapy, which contributes to explain the lower intensity of medical therapy in women compared with men.
Sex bias or unknown confounder?
Women received less evidence-based medications, namely ACE-inhibitors (OR: 0.74; 95% CI: 0.65-0.83) and lipid-modifying agents (OR: 0.77; 95% CI: 0.66-0.88) after adjusting for all known variables including age, history of hypertension, lipid disorders, diabetes, clinical presentation with heart failure, and cardiac catheterization. One potential source of disparities for statin use is the fact that female sex is one of the main independent predictors of the absence of obstructive coronary artery disease. Approximately 20% of women with ACSs have non-obstructive coronary narrowing. 3, 11, 23 Physicians may hesitate to recommend statins in these women as the cost associated with the medical intervention is significant and the potential benefits uncertain. This hypothesis is in accordance with the data available in our study, as PCI and CABG were not predictors of evidence-based therapy underutilization. Evidence-based therapies in women Sex difference in ACE-inhibitor use is more difficult to explain. Clinicians prescribe ACE-inhibitors less aggressively in patient groups where such therapy is likely to result in a lower benefit, a pattern not seen in our study as women more frequently presented with congestive heart failure and a history of hypertension. 24 In addition, women more likely have heart failure with preserved systolic function. 25 Although the efficacy of ACE-inhibitors in this condition is controversial, this may have contributed to underutilization of ACE-inhibitors in women. 26 Other factors, such as social and economical resources, have been related to cardiovascular risk as well as to variations in clinical management. 27 -30 We were unable to adjust for these confounders.
Prior coronary bypass surgery
The only variable to favour the use of evidence-based therapy in the female population was a history of CABG during hospitalization. Indeed, on the one hand, women were much less likely than men to receive CABG (9 vs. 15%). On the other hand, multivariable analysis demonstrated that CABG was associated with a roughly 30% reduction in the odds of receiving ACE-inhibitor therapy at discharge, which is surprising because there are no data to suggest that revascularization attenuates the benefits of ACE-inhibitors. 24 
Limitations
Adherence to evidence-based therapies was not tracked throughout the study period. However, a discharge prescription for evidence-based therapies is the strongest predictor of filling a prescription within 1 year, 17 and female sex has been associated with improved compliance. 30 We did not collect information on absolute and relative contraindications to medications, but it is improbable that such contraindications would entirely account for the observed differences between male and female patients and for the results of the multivariable analysis.
Conclusions
The data from the present study show that, despite excellent guidelines, women with ACSs are still not receiving appropriate cardiac drugs. Underutilization of evidence-based therapies in women with ACSs compared with men is mostly associated with concomitant factors related to the patient's age, the consequences of the disease, and the physician's assessment of patient risk. However, these factors do not fully explain the differences seen in the use of therapies between men and women as female gender remains associated with underutilization of lipid-modifying agents and ACE-inhibitors despite adjustment for these confounders. A better understanding of the determinants of sub-optimal treatment is needed to lead to interventions that can reduce gender disparities and improve ACS outcomes for all women.
